The combination of digilanid C and ES may reduce the over-activation of CGCs during the hypoxic and ischemic phases of CHF by decreasing the signaling pathway associated with JAK1 expression in cardiac tissues, as shown in Figures 5A–E. The gene discussed is JAK1; the disease is congestive heart failure.